Trial reportCanadian respiratory journal2026
The Role of Melatonin in Smoking Cessation and COPD Management: A Randomized Controlled Trial.
Trial report in Canadian respiratory journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundChronic obstructive pulmonary disease (COPD) is a leading global health concern, characterized by persistent airflow obstruction and a significant burden on quality of life. Smoking cessation is critical for COPD management, but nicotine addiction poses challenges. Emerging evidence suggests that melatonin may aid in addiction management, though its efficacy in COPD remains underexplored.
methodsThis randomized, triple-blind, controlled clinical trial evaluated the impact of melatonin on nicotine dependence and COPD outcomes over 180 days. Sixty male COPD patients with a history of smoking were randomized to receive melatonin (5 mg or placebo). Smoking behavior, psychological well-being, and hospitalization rates were assessed using validated scales.
resultsBoth groups exhibited reduced cigarette consumption and improved psychological scores over time, with no significant differences between groups. Hospitalization rates due to COPD exacerbations were lower in the melatonin group (4% vs. 24% in placebo), indicating a nonsignificant trend that warrants further investigation, although the difference was not statistically significant.
conclusionWhile melatonin did not significantly affect smoking cessation or psychological outcomes, the observed reduction in hospitalization rates should be interpreted cautiously as an exploratory finding. Larger, long-term, and adequately powered studies are needed to confirm these results and further investigate the potential role of melatonin as an adjunct therapy in COPD management.
trial registrationIranian Registry of Clinical Trials (IRCT): IRCT20190810044500N25.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.